HC Wainwright Issues Positive Outlook for OKUR Earnings

OnKure Therapeutics, Inc. (NASDAQ:OKUR) – Research analysts at HC Wainwright lifted their Q1 2026 EPS estimates for shares of OnKure Therapeutics in a research note issued on Monday, March 16th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($1.05) per share for the quarter, up from their prior estimate of ($1.15). HC Wainwright currently has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for OnKure Therapeutics’ Q2 2026 earnings at ($0.93) EPS, Q3 2026 earnings at ($0.84) EPS, Q4 2026 earnings at ($0.88) EPS and FY2026 earnings at ($3.66) EPS.

Several other research firms have also recently issued reports on OKUR. Weiss Ratings reiterated a “sell (d-)” rating on shares of OnKure Therapeutics in a research report on Monday, December 22nd. Wall Street Zen raised OnKure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $27.00.

OnKure Therapeutics Stock Down 0.2%

Shares of OnKure Therapeutics stock opened at $4.01 on Wednesday. The stock’s 50-day simple moving average is $2.91 and its 200-day simple moving average is $2.89. OnKure Therapeutics has a 52 week low of $1.70 and a 52 week high of $5.28. The company has a market capitalization of $54.34 million, a price-to-earnings ratio of -0.91 and a beta of 0.45.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.16.

Institutional Trading of OnKure Therapeutics

Several hedge funds have recently bought and sold shares of OKUR. Acorn Capital Advisors LLC grew its position in shares of OnKure Therapeutics by 97.2% during the second quarter. Acorn Capital Advisors LLC now owns 2,839,674 shares of the company’s stock valued at $6,787,000 after purchasing an additional 1,400,000 shares in the last quarter. Highbridge Capital Management LLC increased its holdings in shares of OnKure Therapeutics by 51.2% in the second quarter. Highbridge Capital Management LLC now owns 663,607 shares of the company’s stock worth $1,586,000 after purchasing an additional 224,810 shares during the last quarter. Barclays PLC lifted its position in shares of OnKure Therapeutics by 4,286.8% in the fourth quarter. Barclays PLC now owns 27,242 shares of the company’s stock worth $79,000 after buying an additional 26,621 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of OnKure Therapeutics by 40.7% in the fourth quarter. Renaissance Technologies LLC now owns 247,350 shares of the company’s stock worth $717,000 after buying an additional 71,600 shares in the last quarter. Finally, Prosight Management LP boosted its stake in OnKure Therapeutics by 204.9% during the fourth quarter. Prosight Management LP now owns 816,909 shares of the company’s stock valued at $2,369,000 after buying an additional 548,950 shares during the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.